Apurinic/apyrimidinic endonuclease (APE1), a bifunctional AP endonuclease/redox factor, is important in DNA repair and redox signaling, may be associated with radioresistance. Here we investigate whether targeted inhibition of APE1 can sensitize tumor cells to irradiation in vitro and in vivo. We first constructed chimeric adenoviral vector Ad5/F35 carrying human APE1 siRNA (Ad5/ F35-APE1 siRNA). The infectivity of chimeric Ad5/F35 to LOVO colon cancer cells was greater than that of Ad5. APE1 was strongly expressed and nuclear factor kB (NF-kB), a downstream molecule of APE1, known as a radioresistance factor, was constitutively active in LOVO cells. Infection of LOVO cells with Ad5/F35-APE1 siRNA resulted in a dose-dependent decrease of APE1 protein and AP endonuclease activity in vitro. Ad5/F35-APE1 siRNA significantly enhanced sensitivity of LOVO cells to irradiation in clonogenic survival assays, associated with increased cell apoptosis. The APE1 expression in LOVO cells was induced by irradiation in a dose-dependent manner, accompanied with the enhancement of DNA-binding activity of NF-kB and Ad5/F35-APE1 siRNA effectively inhibited constitutive and irradiation-induced APE1 expression and NF-kB activation. In a subcutaneous nude mouse colon cancer model, Ad5/F35-APE1 siRNA (5 Â 10 8 IU, intratumoral injection) inhibited the expression of APE1 protein in LOVO xenografts, and significantly enhanced inhibition of tumor growth by irradiation. In conclusion, APE1 may be involved as one of the radioresistance factors, and targeted inhibition of APE1 shows an effective means of enhancing tumor sensitivity to radiotherapy.
Introduction
Surgery remains the most effective treatment for colorectal cancer (CRC). During the past decades, adjuvant or neoadjuvant radiotherapy has increasingly been used, together with surgery, to lower the chance of cancer spread or recurrence. 1 These treatment protocols have been found to be effective in the treatment of primarily unresectable cancers and to preserve the sphincter in low-lying rectal cancer therapy. 2, 3 However, in general, adenocarcinomas including CRC tend to be less radioresponsive. Moreover, tumors with similar location, size and histologic subtype display different therapeutic response to radiotherapy. It suggests that intrinsic sensitivity of CRC to radiotherapy is significantly different.
DNA-repair systems, as the molecular basis of defending against environmental damage to cell DNA, are important in maintaining the genomic stabilization and integrity. However, an elevated DNA repair capacity in tumor cells leads to drug or radiation resistance and severely limits the efficacy of these agents. A new and emerging concept designed to sensitize cancer cells to DNA-damaging agents, that is chemotherapy, and/or radiation is inhibition of various proteins in the DNA repair pathways. [4] [5] [6] The human apurinic/apyrimidinic endonuclease (APE1) is an essential enzyme in the base excision repair (BER) pathway, which is responsible for the repair of oxidative and alkylation DNA damage. APE1 accounts for nearly all of the abasic site cleavage activity in most cultured human cell lines, [7] [8] [9] [10] and is essential for the protection of cells against the toxic effects of several classes of DNA-damaging agents. Moreover, APE1 has 3 0 -repair diesterase or phosphatase activity, albeit at 200-fold lower than its AP endonuclease activity. 11 This diesterase activity of APE1 is important in repairing DNA that has been damaged by radiation. Following oxidative stress, ionizing radiation or the chemotherapeutic agent bleomycin, the 3 0 -phosphoglycolate diesterase activity of APE1 removes fragmented sugar residues so that the BER pathway can resolve the damage in DNA. 12 In addition to its DNA repair functions, APE1, also called redox factor-1, participates in other crucial cellular processes, including the response to oxidative stress, regulation of transcription factors, including nuclear factor kB (NF-kB). 13 NF-kB has been shown to be associated with radioresistance in CRC cells. 14 Therefore, as a bifunctional AP endonuclease/redox factor, APE1 may be associated with constitutive and induced radioresistance. Several studies demonstrated that APE1 was overexpressed in several human tumors, [15] [16] [17] [18] [19] [20] and increased APE1 expression had been shown to be associated with radioresistance. 18, 19 So we hypothesize that knockdown of APE1 may enhance the sensitivity of cancer cells to radiotherapy. We have previously shown that APE1 was overexpressed in human osteosarcoma, and its knockdown with synthesized APE1 siRNA enhanced cell apoptosis induction by irradiation. 20 Recombinant adenovirus (Ad) vectors are considered to be a promising gene delivery vehicle of high utility because they are easy to construct, can be produced at high titers and efficiently transduce various types of cells. Ad vectors commonly used in the world, including clinical trials, are composed of Ad serotype 5 (Ad5), which belongs to subgroup C. In recent years, however, it has become apparent that Ad5 vectors have some drawbacks, such as high seroprevalence of anti-Ad5 antibodies in adults and low transduction efficiencies of Ad5 vectors in cells lacking a primary receptor for Ad5, coxsackievirus and adenovirus receptor (CAR). [21] [22] [23] To overcome these limitations of Ad5 vectors, we applied a novel type of chimeric Ad vector Ad5/F35, which was modified by replacing the fiber of type 5 with the fiber of type 35. Ad35 vectors recognize human CD46, not CAR, as a cellular receptor for infection. 24, 25 Human CD46 is expressed in almost all human cells, leading to a broad tropism of Ad35 vectors to human cells. In this study, we first constructed chimeric adenoviral vector Ad5/F35 carrying human APE1 siRNA and examined its infectivity to human CRC cells. Then, we investigated its effects on the expression of APE1 and the sensitivity to radiotherapy in human CRC cells.
Materials and methods

Materials, cell lines and mice
The monoclonal antibody against human APE1 was purchased from Novus Biological (Littleton, CO, USA). Anti-b-actin was purchased from Sigma (St Louis, MO, USA) and anti-Rb from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Plasmids pDC316-EGFP-U6 and pBHG-fiber5/35 (deletion of the E1 and E3 genes) were provided by Vector Gene Technology Company Limited (VGTC, Beijing, China). The human sporadic colon cancer cell line LOVO was purchased from the American Type Culture Collection (Manassas, VA, USA) and 293 cell line from VGTC. LOVO and 293 cells were passaged in RPMI 1640 and Dulbecco's modified Eagle's medium (HyClone, Logan, UT, USA), respectively, supplemented with 10% fetal bovine serum. Specific pathogen free female athymic nude mice, 4-6-week-old, were purchased from Shanghai SLAC Laboratory Animal Co. Ltd (Shanghai, China). The care and use of mice were according to our university's guidelines.
Recombinant adenovirus vectors
We selected the target region of APE1 siRNA according to our previous studies. 20 The siRNA templates were designed and synthesized according to Ambion's siRNA design online tool, and then the two pairs of complementary oligonucleotides (5 0 -GATCCGCTGGTACGACTG GAGTACCTTCAAGAGAGGTACTCCAGTCGTAC CAGACTTTTTTGGAAA-3 0 ; 5 0 -AGCTTTTCCAAAA AAGTCTGGTACGACTGGAGTACCTCTCTTGAAG GTACTCCAGTCGTACCAGCG-3 0 ) were annealed and inserted into a small shuttle plasmid called pDC316-EGFP-U6 at the BamHI and HindIII restriction enzyme sites. The recombinants were identified by sequencing. Then, the obtained shuttle plasmids pDC316-EGFP-U6-APE1 siRNA were cotransfected with adenovirus rescue plasmid pBHG-fiber5/35 (VGTC) into 293 cells to acquire recombinant adenovirus Ad5/F35-APE1 siRNA. The recombinant adenovirus was detected by examining the presence of the cytopathic effect and the expression of enhanced green fluorescent protein (EGFP). The recombinant adenoviruses' titers were measured after amplification and purification by means of TCID50 assay. Ad5-EGFP and Ad5/F35-EGFP, the control adenoviruses, were similarly produced.
Infection with adenoviruses and flow cytometry LOVO cells were infected with Ad5-EGFP and Ad5/F35-EGFP or Ad5/F35-APE1 siRNA with increasing multiplicities of infection (MOI) for 90 min and were then washed to remove the adenoviruses. They were cultured for 24 h and then analyzed for their EGFP intensity using a FACScan (Becton Dickinson, Mountain View, CA) and CellQuest software (Becton Dickinson).
Western blot analysis
Cells were treated as indicated in the text. Western blot was carried out as described previously. 26 Briefly, equal protein aliquots (40 mg for whole cell, 10 mg for nuclear fractions) in each sample were resolved in 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and the proteins transferred onto PVDF membranes. After blocking with 5% non-fat dried milk, the membranes were incubated with a 1:2000 dilution of primary mouse monoclonal antibodies against human APE1, b-actin and retinoblastoma (Rb). The membranes were then incubated with a horseradish peroxidase-conjugated secondary antibody (1:2000; Pierce, Rockford, IL, USA). The proteins were detected by an enhanced chemiluminescence detection system (Pierce), and light emission was captured on Kodak X-ray films.
AP endonuclease assay
The AP endonuclease activities of APE1 were evaluated by well-characterized oligonucleotide cleavage assay. Briefly, a 51-mer oligonucleotide containing a tetrahydrofuran (THF) site, which is analogue of abasic site (AP) at the 22nd position, was 5 0 -end labeled with [g-32 P]ATP. The labeling reaction consisted of 10 pmol of the single stranded oligonucleotide, 2.5 pmol of [g-32 P]ATP, T4 PNK and appropriate kinase buffer in a total volume of 10 ml, incubated for 30 min at 37 1C and 5 min at 95 1C.
Complementary oligonucleotide was then added at 22 1C to form duplex DNA. Activity assays contained 0.5 pmol of labeled duplex oligonucleotide, 1 Â REC Buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 50 mM KCl, 10 mM MgCl2, 1% bovine serum albumin, 0.05% Triton X-100 (pH 7.5)), protein extraction (0-4 mg) in a 10 ml reaction volume and were incubated at 37 1C for 15 min. The reactions were terminated by adding 10 ml formamide without dyes. Equal volumes (20 ml) of the reaction products from assaying AP endonuclease activity were resolved in 20% polyacrylamide gel with 7 M urea in 1 Â Tris-borate EDTA buffer at 300 V for 40 min. Wet gels were autoradiographed at À70 1C overnight.
Clonogenic survival assays LOVO cells were plated in six-well plates at 0.5 Â 10 6 cells per well. One day later, 70% confluent cells were infected with adenoviruses for 90 min and were then washed to remove the adenoviruses. They were cultured for 48 h and then were irradiated at room temperature, in an aerobic atmosphere, using a 6-mV X-ray with a linear accelerators (Elekta, Stockholm, Sweden). Cells received graded doses of irradiation in 1 shot, from 2 to 8 Gy, at a dose rate of 2 Gy min
À1
. Following irradiation, cells were returned to 37 1C incubation and maintained for 10 days. Colonies were fixed and stained in 0.1% crystal violet in absolute ethanol, then counted. Clones of at least 50 cells were counted as one colony. The surviving fraction was normalized to control cell-plating efficiency by dividing the plating efficiency of treated cells by that of control cells. The survival data were computer-fitted to a 'multi-target single-hit' cell-killing model. 27 Apoptosis assay Apoptosis was measured by terminal transferase dUTP nick-end labeling (TUNEL) assay. Cells on glass coverslips were analyzed for apoptosis using the chromogenic TUNEL-POD (Roche Diagnostics, Indianapolis, IN) assay following the manufacturer's protocols, and TUNEL positive cells identified by their dark brown staining. The extent of apoptosis was evaluated by counting the positive brown-stained cells as well as the total number of cells at 10 arbitrarily selected Â 100 microscope fields in a blinded manner.
Electrophoretic mobility shift assay Electrophoretic mobility shift assay (EMSA) was accomplished according to the method described by Zhang et al., 28 with minor modifications. Briefly, 5 mg of nuclear proteins were incubated with [g-32 P]ATP labeled and purified NF-kB consensus double-stranded oligonucleotide and 1 mg ml À1 poly(dI-dC) in 4 Â binding buffer (80% glycerol, 400 mM KCl, 0.8 mM EDTA, 2 mM dithiothreitol, 80 mM HEPES). After incubation at room temperature for 20 min, samples were loaded on a pre-run 5% polyacrylamide gel and run at 100 V for 2 h. The gel was dried, exposed to X-ray film overnight at À70 1C. The resultant bands were quantified using imaging software Quantity One. Anti-Rb immunoblotting with nuclear protein was performed as a loading control as described above. ). Body weight and volume of xenografts were measured in a blinded fashion using callipers every day, and tumor size was calculated according to the formula AB 2 /2, where A is the longest diameter and B is the shortest diameter of the tumor measured in two different planes. Day 0 is the first day of irradiation and tumor volumes represented on graphs begin on day 0.
In vivo experiments
In separate experiments, 15 tumor-bearing mice, on day 11 after cell injection, were randomized into the following three treatment groups (n ¼ 5 animals per group): (a) Control; (b) Ad5/F35-EGFP; (c) Ad5/F35-APE1 siRNA. Mice in groups (a), (b) and (c) were injected directly into the tumors with 50 ml PBS, Ad5/F35-EGFP and Ad5/ F35-APE1 siRNA, respectively. All mice were killed on day 3 post injection for immunohistochemical analysis of APE1 expression. Tumor tissues were fixed in 10% formalin, embedded in paraffin and sectioned.
Immunohistochemical analysis of tumors for APE1 expression After blocking endogenous peroxidase with 3% H 2 O 2 -methanol for 10 min, tumor sections (4 mm) were incubated with a 1:200 dilution of mouse APE1 monoclonal antibody overnight at 4 1C. Sections were rinsed with PBS and incubated with a 1:200 dilution of horseradish peroxidase conjugated goat anti-mouse immunoglobulin G antibody (Pierce) for 30 min. Sections were rinsed with PBS and developed with diaminobenzidine solution for 10 min. Then they were counterstained with haematoxylin. APE1 staining was quantified using computer-assisted image analysis with Image Pro Plus software (Media Cybernetics). The image analysis was done on four random fields (magnification, Â 100) per section from a total of five sections per group.
Statistical analysis
Data were expressed as the mean ± s.d. The statistical significance of differences was determined by one-way analysis of the variance (ANOVA) with computer software SPSS 10.0 (SPSS, Chicago, IL, USA). A value of Po0.05 was considered statistically significant.
Results
Construction of recombinant adenovirus vectors
The shuttle plasmid pDC316-EGFP-U6, in which the resultant APE1 siRNA cDNA was inserted, downstream of the U6 promoter, was established by ligation and then identified by sequencing (data not show). The correct plasmid was named pDC316-EGFP-U6-APE1 siRNA. Then, the shuttle plasmid was cotransfected with adenovirus rescue plasmid pBHG-fiber5/35 into 293 cells to acquire recombinant adenovirus Ad5/F35-APE1 siRNA. The recombinant adenovirus was detected by examining the presence of the cytopathic effect and the expression of EGFP (Figure 1 ). The titer was 1.6 Â 10 10 IU ml À1 after amplification and purification.
Increased infectivity of adenovirus chimeric Ad5/F35 to colorectal cancer cells We examined the transduction efficiency of Ad5-EGFP, Ad5/F35-EGFP and Ad5/F35-APE1 siRNA to the LOVO cells. As the same promoter was used to transcribe the EGFP gene in all the vectors, the EGFP-positive population was primarily determined by the adenovirus infectivity. We thereby regarded the percentage of EGFPpositive cells as putative infectivity of adenoviruses in this study. The infectivity of Ad5/F35-EGFP and Ad5/F35-APE1 siRNA was almost equivalent, but greater than that of Ad5-EGFP (Figure 2) . Similar results were found in other CRC cell lines (data not shown).
Ad5/F35-APE1 siRNA inhibits APE1 expression and AP endonuclease activity Expression of APE1 protein was detected by western blot analysis. As shown in Figures 3a and b , a dose-dependent decrease in APE1 protein expression was observed at 48 h after infection with Ad5/F35-APE1 siRNA in LOVO cells, whereas no change in APE1 protein expression was observed after Ad5/F35-EGFP infection. The inhibition rate of expression of APE1 protein was 95% with 20 MOI of Ad5/F35-APE1 siRNA. In another series of experiments, cells were collected at 48 h following Ad5/F35-APE1 siRNA treatment, and AP endonuclease activity was detected with [g-32 P]ATP-labeled oligonucleotide containing a THF abasic site, which is a substrate for APE1. As shown in Figure 3c , AP endonuclease activity was significantly decreased in a dose-dependent manner after infection with Ad5/F35-APE1 siRNA, compared with Ad5/F35-EGFP.
Radiosensitivity and cell apoptosis in vitro
We then investigated the impact of Ad5/F35-APE1 siRNA and radiotherapy combination therapy on LOVO cells. LOVO cells were treated with an empty adenoviral vector (Ad5/F35-EGFP) or Ad5/F35-APE1 siRNA, and irradiated. Antitumor activity was evaluated using a colony formation assay. The toxicity of Ad5/F35-APE1 siRNA infection in the absence of irradiation was assessed on the basis of plating efficiency. The plating efficiency of LOVO cells infected with 20 MOI of Ad5/F35-EGFP, 10 MOI of Ad5/F35-APE1 siRNA and 20 MOI of Ad5/F35-APE1 siRNA was 52, 49 and 45%, respectively. These plating efficiencies were used to normalize irradiation dose-response curves. We observed a significant dose-dependent decrease in survival of the Ad5/ To investigate the effects of Ad5/F35-APE1 siRNA on apoptosis induction by irradiation in vitro, we measured apoptotic cell by TUNEL assay. Ad5/F35-APE1 siRNA induced a slight increase in apoptotic cells compared with Ad5/F35-EGFP, whereas Ad5/F35-APE1 siRNA increased significantly cell apoptosis induction by irradiation. (Figures 4b and c) .
Ad5/F35-APE1 siRNA inhibits irradiation-induced APE1 expression and activation of NF-jB To investigate the role of APE1 downregulation in potentiation of radiosensitivity by Ad5/F35-APE1 siRNA, we first analyzed the expression of APE1 at 48 h post irradiation. A dose-dependent increase in APE1 protein expression in LOVO cells was observed post irradiation (Figures 5a and b) , possibly promoting radioresistance. Then, we analyzed the expression of APE1 following combined treatment, and found that irradiation-induced APE1 expression was almost completely inhibited by the pretreatment of cells with Ad5/F35-APE1 siRNA (Figures 5c and d) .
APE1 is a multifunctional protein representing a central factor during cell response to oxidative stress through the modulation of transcriptional activation, including NF-kB, 29 a well-known transcription factor critically involved in the survival and radioresistance of cells.
14 To elucidate whether NF-kB is involved in potentiation of radiosensitivity by Ad5/F35-APE1 siRNA, first, the effect of irradiation on NF-kB DNA-binding activity was investigated by EMSA at 3 h post irradiation. We found that NF-kB was constitutively active and induced by irradiation in a dose-dependent manner in LOVO cells (Figures 6a and b) . Then, we investigated the effects of Ad5/F35-APE1 siRNA on constitutive and irradiation-induced activation of NF-kB, and found that it was significantly inhibited by Ad5/F35-APE1 siRNA (Figures 6c and d) .
Ad5/F35-APE1 siRNA inhibits APE1 expression in vivo We investigated the expression of APE1 protein in LOVO xenografts on day 3 post injection of adenoviruses by immunohistochemistry. In control group, intensive nuclear and cytoplasmic immunostaining of APE1 was observed in tumor cells, and the tumors in Ad5/F35-APE1 siRNA-treated group showed significant decreases in both nuclear and cytoplasmic immunostaining of APE1, whereas the APE1 expression in the Ad5/F35-EGFP-treated group was not changed compared with control group (Figure 7) . We have shown that the expression of APE1 protein in LOVO xenografts was inhibited by Ad5/F35-APE1 siRNA. To investigate whether the downregulation of APE1 protein could potentiate the inhibition of tumor growth by irradiation in vivo, tumor-bearing mice were injected intratumorally with Ad5/F35-APE1 siRNA or Ad5/F35-EGFP, and three days later tumors were irradiated with 6 Gy of X-ray. Figure 8 shows that Ad5/F35-APE1 siRNA combined with irradiation caused a significant inhibition of tumor growth compared with Ad5/F35-EGFP þ irradiation or Ad5/F35-APE1 siRNA alone. On day 14, the tumor-inhibition rates of Ad5/F35-APE1 siRNA group, Ad5/F35-EGFP þ irradiation group and Ad5/F35-APE1 siRNA þ irradiation group were 15.06, 41.41 and 70.90%, respectively (Po0.01).
Discussion
The field of cancer therapy is beginning to reap the benefits of our increasing understanding of the molecular basis of cancer. In contrast to conventional surgical interventions or cytotoxic chemotherapy and radiotherapy, a new generation of gene therapy is being specifically directed toward molecular pathways that underlie the malignant phenotype. One of the widely used vectors for cancer gene therapy is Ad, and Ad5 is the most commonly used. Its cellular receptor CAR is ubiquitously expressed in the epithelium but their expression is often downregulated in various types of human tumors [21] [22] [23] and thus compromises the utility of the Ad5 vector. Recent reports have demonstrated that chimeric Ad5, whose fiber structure was substituted with that of type 35 (Ad5/F35) infected more effectively than Ad5 in several types of tumor cells. 23 Moreover, Ad5/F35-based oncolytic adenovirus vector can effectively infect colon cancer cells in vitro and in vivo.
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In this study, we first investigated the infectivity of Ad5 and chimeric Ad5/F35 to human CRC cells and found that chimeric Ad5/F35 infected the tumors more effectively than the unmodified Ad5. It suggests that the chimeric Ad5/F35 are suitable vectors of gene transfer for human CRC cells.
We have previously reported that knockdown with synthesized APE1 siRNA enhanced osteosarcoma cells apoptosis induction by irradiation. 20 In the present study, we found that chimeric adenoviral vector Ad5/F35 carrying human APE1 siRNA (Ad5/F35-APE1 siRNA) Radioresistance and chemoresistance of tumors are major obstacles that often lead to the failure of clinical cancer therapy. An important strategy for improving cancer therapy is the development of approaches that are more selective and mechanistic for overcoming tumor resistance. DNA repair proteins are becoming important targets for enhancing cancer therapy. [4] [5] [6] In particular, APE1 is becoming a leading target due to its central involvement in DNA repair signaling. 31 The BER pathway is essential for the removal of DNA bases damaged by alkylation or oxidation. A key step in BER is the processing of an AP site intermediate by an AP endonuclease. APE1 is the major AP endonuclease in human cells and accounts for 95% of the total AP endonuclease activity, and is essential for the protection of cells against the toxic effects of several classes of DNAdamaging agents. [7] [8] [9] [10] APE1 is active in both and interacts with several proteins including 8-oxoguanine DNA glycosylase , X-ray cross-complementing-1 , proliferating cell nuclear antigen, flap endonuclease 1 and polymerase b. 32 In addition to AP endonuclease activity, APE1 also possesses 3 0 -phosphodiesterase, 3 0 -phosphatase and 3 0 -5 0 -exonuclease functions specific for the 3 0 termini of internal nicks and gaps in DNA. [33] [34] [35] The present study found that APE1 was strongly expressed in LOVO cells and the expression of APE1 was increased by irradiation, probably representing an early event in the cell response to irradiation because of its role in DNA BER, and promoting radioresistance. Ad5/ F35-APE1 siRNA inhibited APE1 expression and AP endonuclease activity in a dose-dependent manner. This suggests that pretreatment with Ad5/F35-APE1 siRNA would potentiate irradiation-induced DNA damage and suppress DNA repair. Moreover, clonogenic assays in vitro showed that the shoulder width (Figure 4a ) was reduced significantly in cells pretreated with Ad5/F35-APE1 siRNA compared with Ad5/F35-EGFP, which indicates that the ability to repair sublethal damage is attenuated in cells pretreated with Ad5/F35-APE1 siRNA.
In addition to DNA BER, APE1 has been shown to activate numerous transcription factors and facilitate their DNA binding via the reduction of a cysteine residue. 36 NF-kB activity was found to be a redox regulated by and dependent on APE1. 13 Our data showed irradiation-induced activation of NF-kB. NF-kB has been linked to radioresistance in CRC cells, 14 and inhibition of NF-kB sensitizes CT26 CRC cells to ionizing radiation. 37 Therefore, the downregulation of NF-kB by Ad5/F35-APE1 siRNA is likely to be responsible for increased radiosensitivity of LOVO cells.
Several studies have reported that APE1 inhibitor could enhance conventional cancer treatment such as radiotherapy. 38, 39 Our previous study has demonstrated that vector-based APE1 siRNA decreased specifically APE1 levels and enhanced the chemosensitivity of multiple myeloma to melphalan. 40 The present study is the first to confirm that adenovirus-mediated transfer of APE1 siRNA enhances sensitivity of human CRC cells to radiotherapy in vitro and in vivo. Therefore, inhibition of APE1 protein by APE1-specific siRNA may be a promising approach when combined with radiotherapy for CRC. Future clinical studies are needed to determine the safety and efficacy of Ad5/F35-APE1 siRNA in combination with radiotherapy in CRC patients. 
